Tags : Multi-Product

Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

Shots: The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia’s pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for cancer patients Samsung Biologics to provide CDO services from cell line development, process development, non-clinical/clinical material manufacturing, to IND submission supporting the global clinical trials […]Read More